Maplight Therapeutics (NASDAQ:MPLT) Shares Up 4.8% – Here’s Why

Maplight Therapeutics, Inc. (NASDAQ:MPLT)’s stock price shot up 4.8% during trading on Friday . The stock traded as high as $19.47 and last traded at $19.47. 21,903 shares were traded during mid-day trading, a decline of 88% from the average session volume of 183,259 shares. The stock had previously closed at $18.58.

Analysts Set New Price Targets

MPLT has been the topic of a number of research analyst reports. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Weiss Ratings initiated coverage on Maplight Therapeutics in a research report on Thursday. They issued a “sell (e)” rating on the stock. Stifel Nicolaus started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $28.00 target price for the company. Jefferies Financial Group initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Maplight Therapeutics Stock Down 3.2%

The stock has a market capitalization of $815.75 million and a price-to-earnings ratio of -0.48. The stock has a 50-day simple moving average of $17.18.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.